Ovarian CancerNCT02769546
Physician-Patient Communication and Expectations Regarding Ovarian Cancer Prognosis
An observational study of Ovarian Cancer, run by Abramson Cancer Center at Penn Medicine at 1 site in United States.
Trial summary
The primary objective is to administer a cross-sectional survey to directly compare the differences patients and physicians hold regarding ovarian cancer prognosis and survival, complications arising from treatment, and counseling on advance directives, living wills, palliative care, and hospice services. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Ovarian Cancer
- What is being tested?
- Surveys
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- Jan 2016to Jan 2018
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: Ovarian Cancer
Who may be able to join
- women over 18 years old with biopsy-confirmed malignancy
- being actively treated or are in surveillance for epithelial ovarian cancer
- have an existing therapeutic relationship with a provider who is participating in the study.
Who cannot join
- patients enrolled in palliative or hospice care programs, patients with a second primary malignancy within the last five years (excluding non-melanoma skin cancer)
- patients who are illiterate or non-English speaking, and patients without decision-making capacity.
- There are no exclusion criteria based on age, gender, economic status or race/ethnicity
Trial locations and contacts
1 site in 1 country.
United States1 site
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104
About this study
The primary objective is to administer a cross-sectional survey to directly compare the differences patients and physicians hold regarding ovarian cancer prognosis and survival, complications arising from treatment, and counseling on advance directives, living wills, palliative care, and hospice services. Overall, the project will pinpoint opportunities for better patient physician communication regarding prognosis and end-of-life care and allow for more informed and tailored decision-making.
- Conditions
- Ovarian Cancer
- Being tested
- Surveys
- Medical subject headings
- Ovarian Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SurveysOther
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of completed surveys and phone interviews
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 May 2016 (estimated)
- Study startJan 2016
- Primary completionJan 2018
- Study completionJan 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ovarian CancerStudies of the same condition, open and under way.
- More trials run by Abramson Cancer Center at Penn MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Ashley Haggerty, MD, Principal investigator, Abramson Cancer Center at Penn Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02769546
- Sponsor's protocol ID
- UPCC 28815
- Status last verified
- Apr 2020
- First submitted
- 10 May 2016
- Last updated
- 2 Apr 2020
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 2 Apr 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Physician-Patient Communication and Expectations Regarding Ovarian Cancer Prognosis
- ClinicalTrials.gov ID
- NCT02769546
- Acronym / sponsor ID
- UPCC 28815
- Conditions
- Ovarian Cancer
- Study type
- Observational
- Recruitment status
- Terminated
- Enrolment
- 50 participants (actual)
- Lead sponsor
- Abramson Cancer Center at Penn MedicineUniversity, hospital or other
- Study start
- Jan 2016
- Primary completion
- Jan 2018 (actual)
- Study completion
- Jan 2018 (actual)
- First posted
- 11 May 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective is to administer a cross-sectional survey to directly compare the differences patients and physicians hold regarding ovarian cancer prognosis and survival, complications arising from treatment, and counseling on advance directives, living wills, palliative care, and hospice services. Overall, the project will pinpoint opportunities for better patient physician communication regarding prognosis and end-of-life care and allow for more informed and tailored decision-making.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Ovarian Cancer
Key inclusion criteria (3 listed)
- women over 18 years old with biopsy-confirmed malignancy
- being actively treated or are in surveillance for epithelial ovarian cancer
- have an existing therapeutic relationship with a provider who is participating in the study.
Key exclusion criteria (3 listed)
- patients enrolled in palliative or hospice care programs, patients with a second primary malignancy within the last five years (excluding non-melanoma skin cancer)
- patients who are illiterate or non-English speaking, and patients without decision-making capacity.
- There are no exclusion criteria based on age, gender, economic status or race/ethnicity
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Surveys | Other | – |
Primary outcome
Number of completed surveys and phone interviews
Time frame: 1 year
Results and safety
The study was stopped early. Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Apr 2020.
Related trials for Ovarian Cancer
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Recruiting
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ovarian Carcinoma
RecruitingPhase 2
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ovarian Cancer, Fallopian Tube Cancer
Active, not recruitingPhase 1/2
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
Colorectal Neoplasms, Breast Neoplasms
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ashley Haggerty, MD principal investigator
Abramson Cancer Center at Penn Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Ovarian Cancer, run by Abramson Cancer Center at Penn Medicine at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 2 Apr 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early. Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of completed surveys and phone interviews (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Apr 2020.